Granules India Limited engages in the production of active pharmaceutical ingredients (APIs) and pharmaceutical formulation intermediates (PFI).
Division
API division
The company’s API facilities are located at Jeedimetla and Bonthapally. The Jeed…
Analysis
Hope premium
Granules India Limited is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is expensive. The owner-earnings multiple stands at 52.2×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 19% a year, against analyst forecasts of 22%. The price, in other words, assumes less than the experts do.
Growth is solid; the safety picture is sturdy. The company scores 17/20 on our value-creation score: strong value creator.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202317
82
2023202420252026
All-time high
82
Jun 2026
All-time low
17
Jan 2023
Average rank
60
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
43
60
82
78
Price/Earnings
57
62
86
74
Price/Book
42
53
73
67
Dividend Yield
31
12
10
36
Value (overall)
48
47
65
73
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.